Loading…
Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice
When prescribing antibiotics, infection eradication rates, local resistance rates, and cost should be among the most essential considerations. is among the most common infections worldwide, and it can lead to burdensome sequela for the patient and the healthcare system, without appropriate treatment...
Saved in:
| Published in: | Life (Basel, Switzerland) Switzerland), 2022-12, Vol.12 (12), p.2038 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c622t-dc11012d4374e6f7ea69bfda286f23aeee0b35dadafe5c45a545eeb9d1d8c0e63 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c622t-dc11012d4374e6f7ea69bfda286f23aeee0b35dadafe5c45a545eeb9d1d8c0e63 |
| container_end_page | |
| container_issue | 12 |
| container_start_page | 2038 |
| container_title | Life (Basel, Switzerland) |
| container_volume | 12 |
| creator | Roberts, Logan T Issa, Peter P Sinnathamby, Evan S Granier, Mallory Mayeux, Holly Eubanks, Treniece N Malone, Kevin Ahmadzadeh, Shahab Cornett, Elyse M Shekoohi, Sahar Kaye, Alan D |
| description | When prescribing antibiotics, infection eradication rates, local resistance rates, and cost should be among the most essential considerations.
is among the most common infections worldwide, and it can lead to burdensome sequela for the patient and the healthcare system, without appropriate treatment. Due to constantly fluctuating resistance rates, regimens must be constantly assessed to ensure effectiveness.
This was a narrative review. The sources for this review are as follows: searching on PubMed, Google Scholar, Medline, and ScienceDirect; using keywords:
, Treatment Options, Clinical Practice.
Multiple antibiotics are prescribed as part of the regimen to thwart high resistance rates. This can lead to unwanted adverse reactions and adherence issues, due to the amount and timing of medication administration, which also may contribute to resistance. Single-capsule combination capsules have reached the market to ease this concern, but brand-only may be problematic for patient affordability. Due to the previously mentioned factors, effectiveness and affordability must be equally considered.
This review will utilize guidelines to discuss current treatment options and give cost considerations to elicit the most effective regimen for the patient. |
| doi_str_mv | 10.3390/life12122038 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_29358bfeef2a42deabad917b08ae8b61</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A750339083</galeid><doaj_id>oai_doaj_org_article_29358bfeef2a42deabad917b08ae8b61</doaj_id><sourcerecordid>A750339083</sourcerecordid><originalsourceid>FETCH-LOGICAL-c622t-dc11012d4374e6f7ea69bfda286f23aeee0b35dadafe5c45a545eeb9d1d8c0e63</originalsourceid><addsrcrecordid>eNptkk1vEzEQhlcIRKvQG2e0EheQSPHH2uvlgBRFQCNValXK2Zq1x8HRZh3s3UL_PQ4pVRZhHzwaP_N6PlwULyk557wh7zvvkDLKGOHqSXHKSC3mtGbN0yP7pDhLaUPykoJKVT0vTrgUQlaEnRZXF9h5E1owA8by-r4L0X8oF-UN3nn8WQZXLscYsR_K24gwbPfW1W7woU-l78tl53tvoCuvY1bwBl8Uzxx0Cc8ezlnx7fOn2-XF_PLqy2q5uJwbydgwt4ZSQpmteF2hdDWCbFpngSnpGAdEJC0XFiw4FKYSICqB2DaWWmUISj4rVgddG2Cjd9FvId7rAF7_cYS41hBzQh1q1nChWofoGFTMIrRgG1q3RAGqVtKs9fGgtRvbLVqTa4zQTUSnN73_rtfhTje1ynnVWeDNg0AMP0ZMg976ZLDroMcwJs1qoShRPGcyK17_g27CGPvcqj0lay4m1BpyAb53Ib9r9qJ6UQuyH73imTr_D5W3xW2eaY_OZ_8k4O0kIDMD_hrWMKakV19vpuy7A2tiSCmie-wHJXrP6OO_l_FXxz18hP_-NP4bURfTXA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2756735329</pqid></control><display><type>article</type><title>Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Roberts, Logan T ; Issa, Peter P ; Sinnathamby, Evan S ; Granier, Mallory ; Mayeux, Holly ; Eubanks, Treniece N ; Malone, Kevin ; Ahmadzadeh, Shahab ; Cornett, Elyse M ; Shekoohi, Sahar ; Kaye, Alan D</creator><creatorcontrib>Roberts, Logan T ; Issa, Peter P ; Sinnathamby, Evan S ; Granier, Mallory ; Mayeux, Holly ; Eubanks, Treniece N ; Malone, Kevin ; Ahmadzadeh, Shahab ; Cornett, Elyse M ; Shekoohi, Sahar ; Kaye, Alan D</creatorcontrib><description>When prescribing antibiotics, infection eradication rates, local resistance rates, and cost should be among the most essential considerations.
is among the most common infections worldwide, and it can lead to burdensome sequela for the patient and the healthcare system, without appropriate treatment. Due to constantly fluctuating resistance rates, regimens must be constantly assessed to ensure effectiveness.
This was a narrative review. The sources for this review are as follows: searching on PubMed, Google Scholar, Medline, and ScienceDirect; using keywords:
, Treatment Options, Clinical Practice.
Multiple antibiotics are prescribed as part of the regimen to thwart high resistance rates. This can lead to unwanted adverse reactions and adherence issues, due to the amount and timing of medication administration, which also may contribute to resistance. Single-capsule combination capsules have reached the market to ease this concern, but brand-only may be problematic for patient affordability. Due to the previously mentioned factors, effectiveness and affordability must be equally considered.
This review will utilize guidelines to discuss current treatment options and give cost considerations to elicit the most effective regimen for the patient.</description><identifier>ISSN: 2075-1729</identifier><identifier>EISSN: 2075-1729</identifier><identifier>DOI: 10.3390/life12122038</identifier><identifier>PMID: 36556402</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antibacterial agents ; Antibiotics ; Antimicrobial agents ; Bacteria ; Campylobacter ; Care and treatment ; Clinical medicine ; clinical practice ; Drug resistance ; Drug resistance in microorganisms ; Drug therapy ; Effectiveness ; Food contamination & poisoning ; Gastric cancer ; Gram-negative bacteria ; Health aspects ; Health services ; Helicobacter infections ; Helicobacter pylori ; High resistance ; Infection ; Infections ; Lymphoma ; Methicillin ; Metronidazole ; Microorganisms ; Neutrophils ; Pathogens ; Patients ; Pharmaceutical research ; Purpura ; Review ; Search engines ; Socioeconomic factors ; Tetracycline ; Tetracyclines ; treatment options ; Ulcers</subject><ispartof>Life (Basel, Switzerland), 2022-12, Vol.12 (12), p.2038</ispartof><rights>COPYRIGHT 2022 MDPI AG</rights><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c622t-dc11012d4374e6f7ea69bfda286f23aeee0b35dadafe5c45a545eeb9d1d8c0e63</citedby><cites>FETCH-LOGICAL-c622t-dc11012d4374e6f7ea69bfda286f23aeee0b35dadafe5c45a545eeb9d1d8c0e63</cites><orcidid>0000-0002-3936-945X ; 0000-0003-0031-1370 ; 0000-0002-5248-3142 ; 0000-0001-7961-3931 ; 0000-0003-0265-6153 ; 0000-0001-6666-9741</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2756735329/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2756735329?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36556402$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roberts, Logan T</creatorcontrib><creatorcontrib>Issa, Peter P</creatorcontrib><creatorcontrib>Sinnathamby, Evan S</creatorcontrib><creatorcontrib>Granier, Mallory</creatorcontrib><creatorcontrib>Mayeux, Holly</creatorcontrib><creatorcontrib>Eubanks, Treniece N</creatorcontrib><creatorcontrib>Malone, Kevin</creatorcontrib><creatorcontrib>Ahmadzadeh, Shahab</creatorcontrib><creatorcontrib>Cornett, Elyse M</creatorcontrib><creatorcontrib>Shekoohi, Sahar</creatorcontrib><creatorcontrib>Kaye, Alan D</creatorcontrib><title>Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice</title><title>Life (Basel, Switzerland)</title><addtitle>Life (Basel)</addtitle><description>When prescribing antibiotics, infection eradication rates, local resistance rates, and cost should be among the most essential considerations.
is among the most common infections worldwide, and it can lead to burdensome sequela for the patient and the healthcare system, without appropriate treatment. Due to constantly fluctuating resistance rates, regimens must be constantly assessed to ensure effectiveness.
This was a narrative review. The sources for this review are as follows: searching on PubMed, Google Scholar, Medline, and ScienceDirect; using keywords:
, Treatment Options, Clinical Practice.
Multiple antibiotics are prescribed as part of the regimen to thwart high resistance rates. This can lead to unwanted adverse reactions and adherence issues, due to the amount and timing of medication administration, which also may contribute to resistance. Single-capsule combination capsules have reached the market to ease this concern, but brand-only may be problematic for patient affordability. Due to the previously mentioned factors, effectiveness and affordability must be equally considered.
This review will utilize guidelines to discuss current treatment options and give cost considerations to elicit the most effective regimen for the patient.</description><subject>Antibacterial agents</subject><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Bacteria</subject><subject>Campylobacter</subject><subject>Care and treatment</subject><subject>Clinical medicine</subject><subject>clinical practice</subject><subject>Drug resistance</subject><subject>Drug resistance in microorganisms</subject><subject>Drug therapy</subject><subject>Effectiveness</subject><subject>Food contamination & poisoning</subject><subject>Gastric cancer</subject><subject>Gram-negative bacteria</subject><subject>Health aspects</subject><subject>Health services</subject><subject>Helicobacter infections</subject><subject>Helicobacter pylori</subject><subject>High resistance</subject><subject>Infection</subject><subject>Infections</subject><subject>Lymphoma</subject><subject>Methicillin</subject><subject>Metronidazole</subject><subject>Microorganisms</subject><subject>Neutrophils</subject><subject>Pathogens</subject><subject>Patients</subject><subject>Pharmaceutical research</subject><subject>Purpura</subject><subject>Review</subject><subject>Search engines</subject><subject>Socioeconomic factors</subject><subject>Tetracycline</subject><subject>Tetracyclines</subject><subject>treatment options</subject><subject>Ulcers</subject><issn>2075-1729</issn><issn>2075-1729</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkk1vEzEQhlcIRKvQG2e0EheQSPHH2uvlgBRFQCNValXK2Zq1x8HRZh3s3UL_PQ4pVRZhHzwaP_N6PlwULyk557wh7zvvkDLKGOHqSXHKSC3mtGbN0yP7pDhLaUPykoJKVT0vTrgUQlaEnRZXF9h5E1owA8by-r4L0X8oF-UN3nn8WQZXLscYsR_K24gwbPfW1W7woU-l78tl53tvoCuvY1bwBl8Uzxx0Cc8ezlnx7fOn2-XF_PLqy2q5uJwbydgwt4ZSQpmteF2hdDWCbFpngSnpGAdEJC0XFiw4FKYSICqB2DaWWmUISj4rVgddG2Cjd9FvId7rAF7_cYS41hBzQh1q1nChWofoGFTMIrRgG1q3RAGqVtKs9fGgtRvbLVqTa4zQTUSnN73_rtfhTje1ynnVWeDNg0AMP0ZMg976ZLDroMcwJs1qoShRPGcyK17_g27CGPvcqj0lay4m1BpyAb53Ib9r9qJ6UQuyH73imTr_D5W3xW2eaY_OZ_8k4O0kIDMD_hrWMKakV19vpuy7A2tiSCmie-wHJXrP6OO_l_FXxz18hP_-NP4bURfTXA</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>Roberts, Logan T</creator><creator>Issa, Peter P</creator><creator>Sinnathamby, Evan S</creator><creator>Granier, Mallory</creator><creator>Mayeux, Holly</creator><creator>Eubanks, Treniece N</creator><creator>Malone, Kevin</creator><creator>Ahmadzadeh, Shahab</creator><creator>Cornett, Elyse M</creator><creator>Shekoohi, Sahar</creator><creator>Kaye, Alan D</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>P64</scope><scope>PATMY</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-3936-945X</orcidid><orcidid>https://orcid.org/0000-0003-0031-1370</orcidid><orcidid>https://orcid.org/0000-0002-5248-3142</orcidid><orcidid>https://orcid.org/0000-0001-7961-3931</orcidid><orcidid>https://orcid.org/0000-0003-0265-6153</orcidid><orcidid>https://orcid.org/0000-0001-6666-9741</orcidid></search><sort><creationdate>20221201</creationdate><title>Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice</title><author>Roberts, Logan T ; Issa, Peter P ; Sinnathamby, Evan S ; Granier, Mallory ; Mayeux, Holly ; Eubanks, Treniece N ; Malone, Kevin ; Ahmadzadeh, Shahab ; Cornett, Elyse M ; Shekoohi, Sahar ; Kaye, Alan D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c622t-dc11012d4374e6f7ea69bfda286f23aeee0b35dadafe5c45a545eeb9d1d8c0e63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibacterial agents</topic><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Bacteria</topic><topic>Campylobacter</topic><topic>Care and treatment</topic><topic>Clinical medicine</topic><topic>clinical practice</topic><topic>Drug resistance</topic><topic>Drug resistance in microorganisms</topic><topic>Drug therapy</topic><topic>Effectiveness</topic><topic>Food contamination & poisoning</topic><topic>Gastric cancer</topic><topic>Gram-negative bacteria</topic><topic>Health aspects</topic><topic>Health services</topic><topic>Helicobacter infections</topic><topic>Helicobacter pylori</topic><topic>High resistance</topic><topic>Infection</topic><topic>Infections</topic><topic>Lymphoma</topic><topic>Methicillin</topic><topic>Metronidazole</topic><topic>Microorganisms</topic><topic>Neutrophils</topic><topic>Pathogens</topic><topic>Patients</topic><topic>Pharmaceutical research</topic><topic>Purpura</topic><topic>Review</topic><topic>Search engines</topic><topic>Socioeconomic factors</topic><topic>Tetracycline</topic><topic>Tetracyclines</topic><topic>treatment options</topic><topic>Ulcers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roberts, Logan T</creatorcontrib><creatorcontrib>Issa, Peter P</creatorcontrib><creatorcontrib>Sinnathamby, Evan S</creatorcontrib><creatorcontrib>Granier, Mallory</creatorcontrib><creatorcontrib>Mayeux, Holly</creatorcontrib><creatorcontrib>Eubanks, Treniece N</creatorcontrib><creatorcontrib>Malone, Kevin</creatorcontrib><creatorcontrib>Ahmadzadeh, Shahab</creatorcontrib><creatorcontrib>Cornett, Elyse M</creatorcontrib><creatorcontrib>Shekoohi, Sahar</creatorcontrib><creatorcontrib>Kaye, Alan D</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Life (Basel, Switzerland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roberts, Logan T</au><au>Issa, Peter P</au><au>Sinnathamby, Evan S</au><au>Granier, Mallory</au><au>Mayeux, Holly</au><au>Eubanks, Treniece N</au><au>Malone, Kevin</au><au>Ahmadzadeh, Shahab</au><au>Cornett, Elyse M</au><au>Shekoohi, Sahar</au><au>Kaye, Alan D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice</atitle><jtitle>Life (Basel, Switzerland)</jtitle><addtitle>Life (Basel)</addtitle><date>2022-12-01</date><risdate>2022</risdate><volume>12</volume><issue>12</issue><spage>2038</spage><pages>2038-</pages><issn>2075-1729</issn><eissn>2075-1729</eissn><abstract>When prescribing antibiotics, infection eradication rates, local resistance rates, and cost should be among the most essential considerations.
is among the most common infections worldwide, and it can lead to burdensome sequela for the patient and the healthcare system, without appropriate treatment. Due to constantly fluctuating resistance rates, regimens must be constantly assessed to ensure effectiveness.
This was a narrative review. The sources for this review are as follows: searching on PubMed, Google Scholar, Medline, and ScienceDirect; using keywords:
, Treatment Options, Clinical Practice.
Multiple antibiotics are prescribed as part of the regimen to thwart high resistance rates. This can lead to unwanted adverse reactions and adherence issues, due to the amount and timing of medication administration, which also may contribute to resistance. Single-capsule combination capsules have reached the market to ease this concern, but brand-only may be problematic for patient affordability. Due to the previously mentioned factors, effectiveness and affordability must be equally considered.
This review will utilize guidelines to discuss current treatment options and give cost considerations to elicit the most effective regimen for the patient.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>36556402</pmid><doi>10.3390/life12122038</doi><orcidid>https://orcid.org/0000-0002-3936-945X</orcidid><orcidid>https://orcid.org/0000-0003-0031-1370</orcidid><orcidid>https://orcid.org/0000-0002-5248-3142</orcidid><orcidid>https://orcid.org/0000-0001-7961-3931</orcidid><orcidid>https://orcid.org/0000-0003-0265-6153</orcidid><orcidid>https://orcid.org/0000-0001-6666-9741</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2075-1729 |
| ispartof | Life (Basel, Switzerland), 2022-12, Vol.12 (12), p.2038 |
| issn | 2075-1729 2075-1729 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_29358bfeef2a42deabad917b08ae8b61 |
| source | Publicly Available Content Database; PubMed Central |
| subjects | Antibacterial agents Antibiotics Antimicrobial agents Bacteria Campylobacter Care and treatment Clinical medicine clinical practice Drug resistance Drug resistance in microorganisms Drug therapy Effectiveness Food contamination & poisoning Gastric cancer Gram-negative bacteria Health aspects Health services Helicobacter infections Helicobacter pylori High resistance Infection Infections Lymphoma Methicillin Metronidazole Microorganisms Neutrophils Pathogens Patients Pharmaceutical research Purpura Review Search engines Socioeconomic factors Tetracycline Tetracyclines treatment options Ulcers |
| title | Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T06%3A01%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Helicobacter%20Pylori:%20A%20Review%20of%20Current%20Treatment%20Options%20in%20Clinical%20Practice&rft.jtitle=Life%20(Basel,%20Switzerland)&rft.au=Roberts,%20Logan%20T&rft.date=2022-12-01&rft.volume=12&rft.issue=12&rft.spage=2038&rft.pages=2038-&rft.issn=2075-1729&rft.eissn=2075-1729&rft_id=info:doi/10.3390/life12122038&rft_dat=%3Cgale_doaj_%3EA750339083%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c622t-dc11012d4374e6f7ea69bfda286f23aeee0b35dadafe5c45a545eeb9d1d8c0e63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2756735329&rft_id=info:pmid/36556402&rft_galeid=A750339083&rfr_iscdi=true |